文献速递造血干细胞移植与细胞治疗

造血细胞移植受者接种ChAdOx1-S(AZD1222)疫苗后SARS-CoV-2中和抗体反应的保留程度优于mRNA疫苗

Greater preservation of SARS-CoV-2 neutralising antibody responses following the ChAdOx1-S (AZD1222) vaccine compared with mRNA vaccines in haematopoietic cell transplant recipients.
PubMed 文献 · Br J Haematol · 2024-11-17

在198例造血干细胞移植(HSCT)/嵌合抗原受体T细胞(CAR-T)受者和96名医护人员中评估三剂祖先株SARS-CoV-2疫苗后的免疫原性。HSCT/CAR-T受者首剂后仅25%产生中和抗体,第二剂后滴度仍低于医护人员;ChAdOx1-S受者产生中和抗体的可能性高于mRNA疫苗,滴度与医护人员相当。

要点

  • HSCT/CAR-T受者首剂后仅25%产生中和抗体,第二剂后滴度仍低于医护人员。
  • 第二剂后较低的中和抗体滴度与年龄较大、使用利妥昔单抗和既往HSCT相关。
  • ChAdOx1-S受者产生中和抗体的可能性高于mRNA疫苗,滴度与医护人员相当。

核心结论

  • HSCT/CAR-T受者首剂免疫原性差,提示最短许可接种间隔可能限制移植后脆弱期;ChAdOx1-S疫苗中和抗体相对保留,凸显在该高危临床队列中评估mRNA疫苗替代平台的重要性。

研究设计与样本

  • 多中心研究评估198例HSCT/CAR-T受者和96名医护人员接种三剂祖先株SARS-CoV-2疫苗后免疫原性的预测因素。

主要发现

  • HSCT/CAR-T受者首剂后仅25%产生中和抗体,第一剂和第二剂后滴度分别比医护人员低167倍和7倍。
  • 第二剂后较低的中和抗体滴度与年龄较大、使用利妥昔单抗和既往HSCT相关。
  • ChAdOx1-S受者产生中和抗体的可能性高于mRNA疫苗受者,滴度与医护人员相当。
  • mRNA疫苗接种后,HSCT/CAR-T受者的中和抗体显著低于医护人员。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Whilst SARS-CoV-2 mRNA vaccines generate high neutralising antibodies (nAb) in most individuals, haematopoietic stem cell transplant (HSCT) and chimeric antigen receptor T-cell (CAR-T) recipients respond poorly. HSCT/CAR-T treatment ablates existing immune memory, with recipients requiring revaccination analogous to being vaccine naive. An optimal revaccination strategy for this cohort has not been defined. Factors predicting immunogenicity following three ancestral SARS-CoV-2 vaccines were assessed in 198 HSCT/CAR-T recipients and 96 healthcare workers (HCWs) recruited to multicentre studies. Only 25% of HSCT/CAR-T recipients generated nAbs following one dose, with titres 167-fold and 7-fold lower than that in HCWs after the first and second doses, respectively. Lower post-second dose nAb titres were associated with older age, rituximab use, and previous HSCT. ChAdOx1-S recipients were more likely to generate nAbs compared with mRNA vaccines, with titres comparable to HCWs. In contrast, nAbs were significantly lower in HSCT/CAR-T recipients than HCWs after mRNA vaccination. The poor first-dose immunogenicity in HSCT/CAR-T recipients suggests a minimum licensed dosing interval could limit the period of vulnerability following HSCT/CAR-T. The relative preservation of nAbs with ChAdOx1-S vaccination highlights the importance of evaluating alternative platforms to mRNA vaccination within this highly vulnerable clinical cohort.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Colton H, Barratt N, Temperton N, et al. Greater preservation of SARS-CoV-2 neutralising antibody responses following the ChAdOx1-S (AZD1222) vaccine compared with mRNA vaccines in haematopoietic cell transplant recipients. Br J Haematol. 2024. PMID: 39551718. doi:10.1111/bjh.19874

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。